Anti-17 alpha-Hydroxyprogesterone polyclonal antibody

Changes in the preconception ambient temperature (PAT) can affect the gametogenesis, disturbing the development of the embryo, but the health risks of PAT on the developing fetus are still unclear. Here, based on the National Free Preconception Health Examination Project in the rural areas of Henan Province, we evaluate the effects of PAT on preterm birth (PTB). Data of 1,231,715 records from self-reported interviews, preconception physical examination, early gestation follow-up, and postpartum follow-up were collected from 1 January 2013 to 31 December 2016. Generalized additive models were used to assess the cumulative and lag effects of PAT upon PTB. The significant cumulative effects of mean temperature within 2 weeks and 3 weeks on the risk of PTB, especially upon late PTB (34-36 weeks) (P < 0.05), were observed. Exposure to extreme heat (> 90th percentile) within 2 weeks (RR = 1.470) and 3 weeks (RR = 1.375) before conception could increase the risk of PTB. After stratifying PTB, exposure to extreme heat within 2 weeks before conception can increase the risks of early (< 34 weeks) and late PTB (P < 0.05). Besides, exposure to extreme cold (< 10th percentile) within 3 weeks or longer before conception can elevate the risk of PTB, especially late PTB. The significant lag effects of temperature changes on the risk of early PTB (lag-8 days or earlier) were observed. In conclusion, the risk of PTB was susceptible to PAT changes within 2 weeks or longer before conception. Our findings provide (i) guidance for rural couples to make pregnancy plans and (ii) scientific evidence for the government to formulate policies to prevent PTB.

We have previously reported that transdermal testosterone attenuates drug-induced QT interval lengthening in older men. However, it is unknown whether this is due to modulation of early ventricular repolarization, late repolarization, or both. In a secondary analysis of a prospective, randomized, double-blind, placebo-controlled three-way crossover study, we determined if transdermal testosterone and oral progesterone attenuate drug-induced lengthening of early and late ventricular repolarization, represented by the electrocardiographic measurements J-T(peak)c and T-peak-T-end, respectively, as well as T-peak-T-end/QT, a measure of transmural dispersion of repolarization. Male volunteers >= 65 years of age (n = 14) were randomized to receive transdermal testosterone 100 mg, oral progesterone 400 mg, or matching transdermal/oral placebo daily for 7 days. On the morning following the seventh day, subjects received intravenous ibutilide 0.003 mg/kg, after which electrocardiograms were performed serially. One subject was excluded due to difficulty in T-wave interpretation. Pre-ibutilide J-T(peak)c was lower during the testosterone phase than during progesterone and placebo (216 +/- 23 vs. 227 +/- 28 vs. 227 +/- 21 ms, P = 0.002). Maximum post-ibutilide J-T(peak)c was also lower during the testosterone phase (233 +/- 22 vs. 246 +/- 29 vs. 248 +/- 23 ms, P < 0.0001). Pre-ibutilide T-peak-T-end was not significantly different during the three phases, but maximum post-ibutilide T-peak-T-end was lower during the testosterone phase (80 +/- 12 vs. 89 +/- 18 vs. 86 +/- 15 ms, P = 0.002). Maximum T-peak-T-end/QT was also lower during the testosterone phase (0.199 +/- 0.023 vs. 0.216 +/- 0.035 vs. 0.209 +/- 0.031, P = 0.005). Progesterone exerted minimal effect on drug-induced lengthening of J-T(peak)c, and no effect on T-peak-T-end or T-peak-T-end/QT. Transdermal testosterone attenuates drug-induced lengthening of both early and late ventricular repolarization in older men.